Amgen wins lawsuit against Regeneron, Sanofi for violating patents
A federal jury decided in favor of Amgen on March 16 in a lawsuit filed against Regeneron Pharmaceuticals and Sanofi for violating patents on a cholesterol reducing drug. In October 2014, Thousand Oaks-based Amgen sued Paris-based Sanofi and Tarrytown, N.Y.-based Regeneron for violating patents on its cholesterol reducing drug Repatha. Sanofi and Regeneron co-developed Praluent Read More →
Amgen to pay dividend of $1 per share
Thousand Oaks-based biotech giant Amgen announced it will pay a second quarter dividend of $1 per share. Amgen increased its first quarter dividend to $1 per share from 79 cents on Dec. 15, which Amgen paid to shareholders during each quarter last year. Amgen will pay the dividend on June 8 to shareholders who own Read More →
Amgen selling $708 million in bonds to Swiss
Thousand Oaks-based biotech giant Amgen said Feb. 23 it will sell about $700 million in bonds on the Swiss market. Amgen said it would sell 700 million Swiss Francs worth of bonds. That equals about $708 million. Amgen submitted the bonds to the Swiss market for pricing Feb. 23 and said it expected to sell Read More →
Thousand Oaks’ Amgen just keeps chugging along
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen Tour of California to include Thousand Oaks to Santa Barbara leg
Organizers of the 12th annual Amgen Tour of California bicycle race announced the full route on Jan. 28. The 2016 race will run 782.7 miles from San Diego to Sacramento from May 15 to May 22. This year will also be just the second time out of 11 previous races that the route runs south Read More →
Amgen revenues up 8 percent in 2015
Despite increased competition from biosimilars and blockbuster mergers by its rivals, Amgen revenues rose 8 percent to $21.67 billion in 2015 from $20.06 billion in 2014. Thousand Oaks-based biotech giant Amgen released its fourth-quarter earnings after markets closed on Jan. 28. Quarterly revenues were also up 4 percent to $5.54 billion in 2015 from $5.33 Read More →
Amgen drug Kyprolis gets another FDA approval
Amgen scored another victory for its breakthrough multiple myeloma drug on Jan. 21. The Thousand Oaks-based biotech giant hit it big when the Food and Drug Administration approved revolutionary multiple myeloma drug Kyprolis for treatments with Kyprolis in combination with another drug. The FDA also approved Kyprolis to treat patients on its own for those Read More →
